Respiratory Medicine
Volume 104, Issue 10 , Pages 1410-1416 , October 2010

Italian real-life experience of omalizumab

  • M. Cazzola

      Affiliations

    • Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina Interna Università di Roma Tor Vergata, Roma, Italy
    • Riabilitazione Respiratoria, IRCSS San Raffaele Pisana, Roma, Italy
    • Corresponding Author InformationCorresponding author. Dipartimento di Medicina Interna, Università di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. Fax: +39 06 72596621.
    • ,
  • G. Camiciottoli

      Affiliations

    • Dipartimento di Medicina Interna, Università di Firenze, Italy
    • ,
  • M. Bonavia

      Affiliations

    • Unità Complessa di. Pneumologia Riabilitativa, Ospedale La Colletta, Arenzano, Italy
    • ,
  • C. Gulotta

      Affiliations

    • Dipartimento di Fisiopatologia Cardio-Toracica, Ospedale San Luigi Gonzaga, Orbassano, Italy
    • ,
  • A. Ravazzi

      Affiliations

    • Centro di Medicina Toracica, Ospedale Sant’Anna, Como, Italy
    • ,
  • A. Alessandrini

      Affiliations

    • Dipartimento di Medicina Generale, Ospedale di Abbiategrasso, Italy
    • ,
  • M.F. Caiaffa

      Affiliations

    • Dipartimento di Allergologia e Immunologia Clinica, Università di Foggia, Italy
    • ,
  • A. Berra

      Affiliations

    • Unità Complessa di Pneumologia, Ospedale Giovanni da Procida, Salerno, Italy
    • ,
  • P. Schino

      Affiliations

    • Unità di Fisiopatologia Respiratoria, Ospedale Generale F. Miulli, Acquaviva delle Fonti, Italy
    • ,
  • P.L. Di Napoli

      Affiliations

    • Unità di Fisiopatologia Respiratoria, Ospedale Generale F. Miulli, Acquaviva delle Fonti, Italy
    • ,
  • R. Maselli

      Affiliations

    • Dipartimento di Medicina Sperimentale e Clinica, Sezione di Malattie dell’Apparato Respiratorio, Università di Catanzaro, Italy
    • ,
  • G. Pelaia

      Affiliations

    • Dipartimento di Medicina Sperimentale e Clinica, Sezione di Malattie dell’Apparato Respiratorio, Università di Catanzaro, Italy
    • ,
  • E. Bucchioni

      Affiliations

    • Dipartimento Medico, Novartis Italia, Origgio, Italy
    • ,
  • P.L. Paggiaro

      Affiliations

    • Dipartimento Cardio-Toracico, Università di Pisa, Italy
    • ,
  • L. Macchia

      Affiliations

    • Dipartimento di Allergologia e Immunologia Clinica, Università di Bari, Italy

Received 24 December 2009 ,Accepted 15 April 2010.

References 

  1. Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J. 2002;20:260–267
  2. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J. 1996;9:636–642
  3. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic IgE-mediated asthma. Br J Clin Pharmacol. 2009;68:61–76
  4. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103:1098–1113
  5. Pesko LJ. Omalizumab has a place in therapy for asthma disease management. J Manag Care Pharm. 2009;15:284–288
  6. Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?. Respir Med. 2005;99:11–19
  7. EMEA Xolair® SmPC. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xolair/H-606-PI-en.pdf[accessed: 22.06.09]
  8. André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose–response relationship. Int Arch Allergy Immunol. 2003;131:111–118
  9. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19:491–498
  10. Town I. Applying the results of randomised control trials on asthma. Thorax. 2007;62(3):195–196
  11. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al. External validity of randomised controlled trials in asthma: to whom the results of the trials apply?. Thorax. 2007;62:219–223
  12. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102:71–76
  13. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103:1725–1731
  14. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. I. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103:1633–1642
  15. Niven RA. UK survey of oral corticosteroid use in patients treated with omalizumab. Thorax. 2007;62(Suppl. 3):A98

PII: S0954-6111(10)00192-7

doi: 10.1016/j.rmed.2010.04.013

Respiratory Medicine
Volume 104, Issue 10 , Pages 1410-1416 , October 2010

Article Tools

* Image Usage & Resolution